Are There Low-penetrance TP53 Alleles? Evidence from Childhood Adrenocortical Tumors

Overview

Journal Am J Hum Genet

Publisher Cell Press

Specialty Genetics

Date 1999 Sep 16

PMID 10486318

Citations 73

Authors

J M Varley

G McGown

M Thorncroft

L A James

G P Margison

G Forster

D G Evans

M Harris

A M Kelsey

J M Birch

Affiliations

Soon will be listed here.

Abstract

We have analyzed a panel of 14 cases of childhood adrenocortical tumors unselected for family history and have identified germline TP53 mutations in >80%, making this the highest known incidence of a germline mutation in a tumor-suppressor gene in any cancer. The spectrum of germline TP53 mutations detected is remarkably limited. Analysis of tumor tissue for loss of constitutional heterozygosity, with respect to the germline mutant allele and the occurrence of other somatic TP53 mutations, indicates complex sequences of genetic events in a number of tumors. None of the families had cancer histories that conformed to the criteria for Li-Fraumeni syndrome, but, in some families, we were able to demonstrate that the mutation had been inherited. In these families there were gene carriers unaffected in their 40s and 50s, and there were others with relatively late-onset cancers. These data provide evidence that certain TP53 alleles confer relatively low penetrance for predisposition to the development of cancer, and they imply that deleterious TP53 mutations may be more frequent in the population than has been estimated previously. Our findings have considerable implications for the clinical management of children with andrenocortical tumors and their parents, in terms of both genetic testing and the early detection and treatment of tumors.

Citing Articles

Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery.

ONeill A, Ribeiro R, Pinto E, Clay M, Zambetti G, Orr B Cancer Manag Res. 2024; 16:1141-1153.

PMID: 39263332 PMC: 11389717. DOI: 10.2147/CMAR.S348725.

Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective.

Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R EJC Paediatr Oncol. 2023; 2.

PMID: 37829670 PMC: 10566015. DOI: 10.1016/j.ejcped.2023.100024.

Preclinical Models of Adrenocortical Cancer.

Sedlack A, Hatfield S, Kumar S, Arakawa Y, Roper N, Sun N Cancers (Basel). 2023; 15(11).

PMID: 37296836 PMC: 10251941. DOI: 10.3390/cancers15112873.

Peripheral precocious puberty in Li-Fraumeni syndrome: a case report and literature review of pure androgen-secreting adrenocortical tumors.

Ryckx S, De Schepper J, Giron P, Maes K, Vaeyens F, Wilgenhof K J Med Case Rep. 2023; 17(1):195.

PMID: 37179382 PMC: 10183130. DOI: 10.1186/s13256-023-03889-y.

Pediatric adrenocortical carcinoma.

Ilanchezhian M, Varghese D, Glod J, Reilly K, Widemann B, Pommier Y Front Endocrinol (Lausanne). 2022; 13:961650.

PMID: 36387865 PMC: 9659577. DOI: 10.3389/fendo.2022.961650.

References

James L, Kelsey A, Birch J, Varley J . Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br J Cancer. 1999; 81(2):300-4. PMC: 2362872. DOI: 10.1038/sj.bjc.6990691. View

Sedlacek Z, Kodet R, Kriz V, Seemanova E, Vodvarka P, Wilgenbus P . Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br J Cancer. 1998; 77(7):1034-9. PMC: 2150131. DOI: 10.1038/bjc.1998.172. View

Hamelin R, Barichard F, Henry I, Junien C, Thomas G . Single base pair germ-line deletion in the p53 gene in a cancer predisposed family. Hum Genet. 1994; 94(1):88-90. DOI: 10.1007/BF02272849. View

Lubbe J, von Ammon K, Watanabe K, Hegi M, Kleihues P . Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. Brain Pathol. 1995; 5(1):15-23. DOI: 10.1111/j.1750-3639.1995.tb00572.x. View

Harbour J . Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening. Ophthalmology. 1998; 105(8):1442-7. DOI: 10.1016/S0161-6420(98)98025-3. View

Moutou C, Le Bihan C, Chompret A, Poisson N, Brugieres L, Bressac B . Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. Cancer. 1996; 78(7):1483-91. DOI: 10.1002/(sici)1097-0142(19961001)78:7<1483::aid-cncr16>3.0.co;2-w. View

Giunta C, Youil R, Venter D, Chow C, Somers G, Lafferty A . Rapid diagnosis of germline p53 mutation using the enzyme mismatch cleavage method. Diagn Mol Pathol. 1996; 5(4):265-70. DOI: 10.1097/00019606-199612000-00007. View

Horio Y, Suzuki H, Ueda R, Koshikawa T, Sugiura T, Ariyoshi Y . Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene. 1994; 9(4):1231-5. View

Grayson G, Moore S, Schneider B, Saldivar V, Hensel C . Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. Am J Pediatr Hematol Oncol. 1994; 16(4):341-7. View

10.

Lohmann D, Brandt B, HOPPING W, Passarge E, Horsthemke B . Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum Genet. 1994; 94(4):349-54. DOI: 10.1007/BF00201591. View

11.

Wagner J, Portwine C, Rabin K, Leclerc J, Narod S, Malkin D . High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst. 1994; 86(22):1707-10. DOI: 10.1093/jnci/86.22.1707. View

12.

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

13.

Hisada M, Garber J, Fung C, Fraumeni Jr J, Li F . Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90(8):606-11. DOI: 10.1093/jnci/90.8.606. View

14.

Malkhosyan S, Rampino N, Yamamoto H, Perucho M . Frameshift mutator mutations. Nature. 1996; 382(6591):499-500. DOI: 10.1038/382499a0. View

15.

Bardeesy N, Falkoff D, Petruzzi M, Nowak N, Zabel B, Adam M . Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994; 7(1):91-7. DOI: 10.1038/ng0594-91. View

16.

Birch J, Heighway J, Teare M, Kelsey A, Hartley A, Tricker K . Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer. 1994; 70(6):1176-81. PMC: 2033684. DOI: 10.1038/bjc.1994.468. View

17.

Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Hirata Y, Mizoguchi H . Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst. 1992; 84(9):703-7. DOI: 10.1093/jnci/84.9.703. View

18.

Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A . A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996; 380(6570):152-4. DOI: 10.1038/380152a0. View

19.

Parsons R, Myeroff L, Liu B, WILLSON J, Markowitz S, Kinzler K . Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995; 55(23):5548-50. View

20.

Birch J, Blair V, Kelsey A, Evans D, Harris M, Tricker K . Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998; 17(9):1061-8. DOI: 10.1038/sj.onc.1202033. View